

**Claims:**

1. A combination of (a) an ATP-competitive inhibitor of c-abl kinase activity and (b) with (b) two or more other antineoplastic agents for simultaneous, separate or sequential use.
2. The combination according to claim 1 where the ATP-competitive inhibitor of c-abl kinase activity (a) is N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine, or a pharmaceutically acceptable salt thereof.
3. The combination according to claim 1 where the ATP-competitive inhibitor of c-abl kinase activity (a) is N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine, or a pharmaceutically acceptable salt thereof, and (b) the two or more antineoplastic agents are selected from purine nucleoside analogs and topoisomerase II inhibitors which are independently present in free form or as pharmaceutically acceptable salts.
4. The combination according to claim 1 where the ATP-competitive inhibitor of c-abl kinase activity (a) is N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine, or a pharmaceutically acceptable salt thereof, and (b) the two or more antineoplastic agents are selected from Idarubicine, Fludarabine and ara-C which are independently of each other present in free form or as pharmaceutically acceptable salts.
5. A method of treating a warm-blooded animal suffering from a proliferative disease, comprising administering to said animal a combination which comprises (a) an ATP-competitive inhibitor of c-abl kinase activity and (b) two or more other antineoplastic agents, where the active compounds falling under (a) and/or (b) are independently of each other in free form or in the form of pharmaceutically acceptable salts, in a dose that is pharmaceutically effective in the treatment of said disease.
6. The method according to claim 5 where component (a) is (N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine, or a pharmaceutically acceptable salt thereof.

7. The method according to claim 5 where component (a) is N-[5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidine-amine, or a pharmaceutically acceptable salt thereof, and component (b) is a combination of two or more of the compounds selected from purine nucleoside analogs and topoisomerase II inhibitors, independently in free form or as pharmaceutically acceptable salts.
8. The method according to claim 5 where component (a) is N-[5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidine-amine, or a pharmaceutically acceptable salt thereof, and component (b) includes two or more of the compounds selected from Idarubicine, Fludarabine and ara-C which are independently of each other present in free form or as pharmaceutically acceptable salts.
9. The method according to claim 5 where the proliferative disease is a leukaemia.
10. A pharmaceutical composition comprising a combination of (a) an ATP-competitive inhibitor of c-abl kinase activity with (b) two or more other antineoplastic agents and optionally at least one pharmaceutically acceptable carrier for the delay of progression or treatment of a proliferative disease in a warm-blooded animal, especially a human, in need of such treatment.
11. The pharmaceutical composition according to claim 10 where component (a) is N-[5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidine-amine, or a pharmaceutically acceptable salt thereof.
12. The pharmaceutical composition according to claim 10 where component (a) is N-[5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidine-amine, or a pharmaceutically acceptable salt thereof, and component (b) includes two or three, preferably two, further antineoplastic agents selected from purine nucleoside analogs and topoisomerase II inhibitors, or pharmaceutically acceptable salts thereof.
13. The pharmaceutical composition according to claim 10 where component (a) is N-[5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl]-4-(3-pyridyl)-2-pyrimidine-amine, or a pharmaceutically acceptable salt thereof, and component (b) includes two or more of the compounds selected from Idarubicine, Fludarabine and ara-C

which are independently of each other present in free form or as pharmaceutically acceptable salts.

14. A commercial package comprising (a) an ATP-competitive inhibitor of c-abl kinase activity and (b) two or more other antineoplastic agents, where the active compounds falling under (a) and/or (b) are independently of each other in free form or in the form of pharmaceutically acceptable salts, for simultaneous, chronically staggered or (less preferably) separate use in the delay of progression or treatment of a proliferative disease.